* Elutia (NASDAQ:ELUT [https://seekingalpha.com/symbol/ELUT]) said on Tuesday that it has entered into a definitive agreement to sell its EluPro and CanGaroo bioenvelopes, designed to protect patients receiving implantable medical devices, to Boston Scientific Corporation (NYSE:BSX [https://seekingalpha.com/symbol/BSX]) for $88 million in cash.
* The deal is expected to close in the fourth quarter of 2025.
* The transaction will help Elutia to eliminate outstanding debt, substantially resolve litigation from the company’s previously divested Orthobiologics business, and leaves the it with a significantly reduced burn rate.
* It will also fully funds advancement and commercialization of NXT-41 and NXT-41x, creating a clear path to cash-flow positive operations without shareholder dilution.
* BSX +0.24% premarket to $108.4.
* Source: Press Release [https://seekingalpha.com/pr/20225918-elutia-announces-sale-of-bioenvelope-business-to-boston-scientific-corporation-for-88-million]
MORE ON BOSTON SCIENTIFIC, ELUTIA
* Boston Scientific Corporation Is Expensive But Worth It [https://seekingalpha.com/article/4811771-boston-scientific-corp-is-expensive-but-worth-it]
* Elutia targets $20M EluPro revenue run rate and NXT-41 launch in H2 2026 while advancing hospital penetration [https://seekingalpha.com/news/4485842-elutia-targets-20m-elupro-revenue-run-rate-and-nxtminus-41-launch-in-h2-2026-while-advancing]
* Boston Scientific raises 2025 organic revenue growth outlook to 14%-15% amid strong cardiovascular performance [https://seekingalpha.com/news/4470788-boston-scientific-raises-2025-organic-revenue-growth-outlook-to-14-percentminus-15-percent]
Boston Scientific buys Elutia's bioenvelope business for $88 million
Published 2 months ago
Sep 9, 2025 at 12:56 PM
Positive
Auto